X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (99) 99
female (64) 64
hematology (64) 64
adult (63) 63
male (63) 63
middle aged (62) 62
transplantation (44) 44
aged (35) 35
hematopoietic stem cell transplantation (33) 33
transplantation, homologous (30) 30
oncology (28) 28
adolescent (22) 22
index medicus (22) 22
treatment outcome (21) 21
colony-stimulating factor (20) 20
stem cells (19) 19
filgrastim (17) 17
hematopoietic stem cells (17) 17
leukemia (17) 17
immunology (16) 16
recombinant proteins (16) 16
bone-marrow transplantation (15) 15
follow-up studies (15) 15
recurrence (15) 15
chemotherapy (14) 14
combined modality therapy (14) 14
g-csf (14) 14
high-dose chemotherapy (14) 14
survival rate (14) 14
vidarabine - analogs & derivatives (14) 14
bone-marrow-transplantation (13) 13
engraftment (13) 13
hematopoietic stem cell transplantation - methods (13) 13
transplantation, autologous (13) 13
article (12) 12
disease-free survival (12) 12
remission induction (12) 12
retrospective studies (12) 12
rituximab (12) 12
transplantation conditioning - methods (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
bone marrow transplantation (11) 11
child (11) 11
hematopoietic stem cell transplantation - adverse effects (11) 11
non-hodgkins-lymphoma (11) 11
stem cell transplantation (11) 11
vidarabine - administration & dosage (11) 11
abridged index medicus (10) 10
animals (10) 10
bone-marrow (10) 10
care and treatment (10) 10
chronic myelogenous leukemia (10) 10
graft vs host disease - prevention & control (10) 10
hematopoietic stem cells - cytology (10) 10
progenitor cells (10) 10
survival analysis (10) 10
therapy (10) 10
versus-host-disease (10) 10
acute disease (9) 9
cancer (9) 9
granulocyte colony-stimulating factor - pharmacology (9) 9
leukapheresis (9) 9
lymphoma (9) 9
peripheral-blood (9) 9
stem-cells (9) 9
survival (9) 9
versus-host disease (9) 9
allogeneic transplantation (8) 8
antibodies, monoclonal, murine-derived (8) 8
antineoplastic agents - therapeutic use (8) 8
bone marrow (8) 8
graft vs host disease - etiology (8) 8
granulocyte colony-stimulating factor - therapeutic use (8) 8
hematopoietic stem cell mobilization - methods (8) 8
normal donors (8) 8
risk factors (8) 8
antibodies, monoclonal - therapeutic use (7) 7
chronic lymphocytic-leukemia (7) 7
cyclophosphamide - administration & dosage (7) 7
graft survival (7) 7
granulocyte colony-stimulating factor - administration & dosage (7) 7
granulocyte colony-stimulating factor - adverse effects (7) 7
hematology, oncology and palliative medicine (7) 7
hematopoietic stem cells - drug effects (7) 7
leukemia, lymphocytic, chronic, b-cell - therapy (7) 7
leukocyte count (7) 7
prognosis (7) 7
stem-cell transplantation (7) 7
transplantation chimera (7) 7
young adult (7) 7
allogeneic blood stem cell transplantation (6) 6
antigens, cd34 (6) 6
autologous transplantation (6) 6
biotechnology & applied microbiology (6) 6
blood donors (6) 6
cell biology (6) 6
devices for introducing media into, or onto, the body (6) 6
devices for producing or ending sleep or stupor (6) 6
devices for transducing body media or for taking media fromthe body (6) 6
etoposide - administration & dosage (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 24, pp. 2305 - 2315
Journal Article
Blood, ISSN 0006-4971, 11/2001, Volume 98, Issue 10, pp. 2900 - 2908
Hematopoietic stem cells from 4 different sources have been or are being used for the reconstitution of lymphohematopoietic function after myeloablative,... 
ALLOGENEIC BLOOD | PROGENITOR CELLS | CYTOKINE PRODUCTION | COLONY-STIMULATING FACTOR | IMMUNE RECONSTITUTION | TELOMERASE ACTIVITY | NORMAL DONORS | FOLLOW-UP | HEMATOLOGY | VERSUS-HOST DISEASE | RANDOMIZED TRIAL | T-Lymphocyte Subsets - immunology | Neutrophils - cytology | Graft vs Host Disease - epidemiology | Follow-Up Studies | Humans | Hematopoietic Stem Cell Transplantation - mortality | Liver - embryology | Filgrastim | Transplantation, Homologous | Multicenter Studies as Topic | Hematopoietic Stem Cell Transplantation - adverse effects | Registries | Leukocyte Count | Retrospective Studies | Monocytes - physiology | Graft vs Host Disease - etiology | Granulocyte Colony-Stimulating Factor - adverse effects | Blood Cells - transplantation | Lymphocyte Activation | Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology | Graft Survival | Immunophenotyping | Fetal Blood - cytology | Recombinant Proteins - pharmacology | Organ Specificity | Randomized Controlled Trials as Topic | Monocytes - drug effects | Granulocyte Colony-Stimulating Factor - pharmacology | Leukapheresis | Platelet Count | Bone Marrow Transplantation - mortality | Tissue and Organ Procurement - methods | Bone Marrow Transplantation - adverse effects | Liver - cytology | Hematopoietic Stem Cell Mobilization - adverse effects | Hematopoietic Stem Cell Transplantation - methods | Tissue Donors | Chronic Disease | Hematopoietic Stem Cells
Journal Article
Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, ISSN 1078-0432, 05/2018, Volume 24, Issue 10, pp. 2304 - 2311
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or... 
Transplants & implants | Clinical trials | Stem cell transplantation | Transplantation | Cytarabine | Melphalan | Remission | Conditioning | Medical research | Autografts | Cell survival | Etoposide | Rituximab | Patients | Survival | Lymphoma | Yttrium isotopes | Chemotherapy | Lymphocytes B | Experimental design | Stem cells | Lymphomas | Yttrium | Cancer | B-cell lymphoma
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 22, pp. 5957 - 5964
Anti-HLA donor-specific Abs (DSAs) have been reported to be associated with graft failure in mismatched hematopoietic stem cell transplantation; however, their... 
ANTIBODIES | SURVIVAL | ADULT PATIENTS | ENGRAFTMENT | BONE-MARROW TRANSPLANTATION | HIGH-RESOLUTION | LEUKEMIA | RECIPIENTS | HEMATOLOGY | DISPARITY | PROGRAM
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2012, Volume 18, Issue 12, pp. 1835 - 1844
Journal Article
Blood, ISSN 0006-4971, 06/2008, Volume 111, Issue 12, pp. 5530 - 5536
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 18, pp. 4144 - 4152
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 6, pp. 718 - 723
Lenalidomide is an agent that has shown great activity in patients with multiple myeloma (MM). However, studies have suggested that this drug negatively... 
Hematology, Oncology and Palliative Medicine | Myeloma | Stem cell mobilization | Autotransplant | COMBINATION THERAPY | NEWLY-DIAGNOSED MYELOMA | PHASE-2 | THALIDOMIDE | BORTEZOMIB | IMMUNOLOGY | CHEMOTHERAPY | TRANSPLANTATION | PLUS DEXAMETHASONE | REFRACTORY MYELOMA | HEMATOLOGY | MELPHALAN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hematopoietic Stem Cell Mobilization - methods | Humans | Middle Aged | Heterocyclic Compounds - pharmacology | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Recombinant Proteins | Filgrastim | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - administration & dosage | Multiple Myeloma - drug therapy | Granulocyte Colony-Stimulating Factor - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Treatment Failure | Angiogenesis Inhibitors - therapeutic use | Vincristine - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacology | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Multiple Myeloma - surgery | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Multiple Myeloma - blood | Thalidomide - adverse effects | Ifosfamide - pharmacology | Dexamethasone - administration & dosage | Heterocyclic Compounds - administration & dosage | Risk Factors | Etoposide - pharmacology | Etoposide - administration & dosage | Combined Modality Therapy | Thalidomide - administration & dosage | Granulocyte Colony-Stimulating Factor - pharmacology | Leukapheresis | Ifosfamide - administration & dosage | Cyclophosphamide - pharmacology | Aged | Multiple Myeloma - radiotherapy | Thalidomide - therapeutic use | Peripheral Blood Stem Cell Transplantation | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Care and treatment | Granulocyte colony-stimulating factor | Analysis | Multiple myeloma | Stem cells | Transplantation | Angiogenesis inhibitors | Cancer | Index Medicus
Journal Article